GCC Genomic Characterization Centers

GCC 基因组表征中心

• 批准号: 8940864
• 负责人: DAVID HEIMBROOK
• 金额: $ 1291.9万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-26 至 2018-09-25
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8940864
• 关键词: Address; Biopsy; Biopsy Specimen; Cancer Model; Cancer Patient; Cancer cell line; Cataloging; Catalogs; Clinical Data; Clinical Trials; Collection; Colon Carcinoma; Contractor; DNA; Data; Data Set; Databases; Deposition; Derivation procedure; Development; Enrollment; Genes; Genomics; Goals; Histology; Human; In Vitro; Institution; Lead; Legal; Lung Adenocarcinoma; Malignant Neoplasms; Mission; Modeling; Molecular; Mutate; Mutation; National Cancer Institute; Office of Cancer Genomics; Oncogenic; Ovarian Carcinoma; Pathogenesis; Patients; Process; Proteins; RNA; Research Project Grants; Resistance; Sampling; Science; Site; Source; Specimen; Structure; The Cancer Genome Atlas; Therapeutic; Tissue Sample; Tissues; Work; Xenograft procedure; analytical tool; base; cancer genome; cancer genomics; cohort; falls; improved; material transfer agreement; payment; prevent; programs; repository; response; tumor

The Center for Cancer Genomics (CCG) at the National Cancer Institute (NCI) was established in 2011 with a mission to lead the NCI efforts in generating critical datasets required to catalog the alterations seen in human tumors, coordinating data unification and sharing efforts, and supporting development of analytical tools and computational approaches aimed at improving our understanding of the large-scale, multidimensional data. CCG also has the goal of developing and applying cutting-edge genomic science to prevent cancer and better treat cancer patients, for example in the context of NCI-supported clinical trials. Currently, several large-scale cancer genome research projects fall under the CCG umbrella including those managed by The Cancer Genome Atlas (TCGA) Program Office and the Office of Cancer Genomics (OCG). The CCG is initiating a variety of new projects that require the genomic analysis of cancer specimens and cancer models (e.g. human cancer cell lines). Broadly, the goals of these initiatives include the elucidation of pathogenetic mechanisms in cancer and how genomic alterations in cancer influence the response to treatment. One such effort is the recently initiated Cancer Driver Discovery Program (CDDP), which aims to identify genes that acquire “driver mutations” in 2% or more cases of cancers of a particular histology. The CDDP pilot has been launched with initial focus on three tumor types – lung adenocarcinoma, colon carcinoma and ovarian carcinomas – but will consider other tumor types as well. By sequencing biopsies in larger numbers than has occurred in the TCGA program (i.e. >500), the CDDP will have the statistical power to discover new recurrently mutated genes in cancer that may drive the oncogenic process. Another program supported by this Yellow Task would be the Clinical Trial Sequencing Project (CTSP), in which CCG is working with DCTD to conduct comprehensive genomic analysis of cancer biopsy specimens from patients enrolled on NCI-sponsored clinical trials, with the goal of identifying the molecular basis for therapeutic response and resistance. A third CCG initiative, termed the Human Cancer Models Program (HCMP), will include the genomic analysis of newly created human cancer models growing in vitro or in xenografts. This Yellow Task is not limited to support for genomic analyses within CDDP, CTSP and HCMP, but rather will enable CCG to conduct similar analyses in other cohorts of cancer specimens or models that address key questions in cancer pathogenesis and treatment. This Yellow Task supports a range of activities necessary for the conduct of the genomic analyses outlined above. First, the contractor will support the acquisition of tissue samples and cancer models for CCG-sponsored projects. It is expected that accrual of tumors will mainly come from collections existing at the NCI Cooperative Groups or similar entities that have obtained the specimens in the context of large-scale well-annotated clinical trials. However, other sources of tissues are not precluded and are in scope for this task order. The accrual process for samples and associated clinical data will involve reimbursement of a modest amount to the participating institutions in a single payment structure. Second, this Yellow Task supports the Biospecimen Core Repository (BCR), which provides CCG with support for the acquisition of cancer biopsy samples, the derivation of molecular analytes (DNA, RNA and protein), and the curation of clinical data associated with CCG-sponsored genomic studies. Additionally, the BCR will produce documents (Material Transfer Agreements, MTA) that codify the legal relationship between the Tissue Source Site(s) (TSS), the Genomic Characterization Center(s) (GCC) and the BCR. Finally, this Yellow Task supports the establishment of Genomic Characterization Centers (GCCs), which will produce molecular data of various types from the analytes provided by the BCR and deposit said data in a format that is compatible with other large-scale genomics projects sponsored by CCG. Deposition of data will be done at a database to be designated by the Program Office (PO).

美国国家癌症研究所 (NCI) 的癌症基因组学中心 (CCG) 成立于 2011 年，其使命是领导 NCI 生成编目人类肿瘤变化所需的关键数据集、协调数据统一和共享工作，以及支持开发分析工具和计算方法，旨在提高我们对大规模、多维数据的理解，CCG 的目标还包括开发和应用尖端基因组科学来预防癌症和更好地治疗癌症患者。目前，CCG 旗下有多个大型癌症基因组研究项目，包括由癌症基因组图谱 (TCGA) 项目办公室和癌症基因组学办公室 (OCG) 管理的项目。 CCG 正在启动各种需要对癌症样本和癌症模型（例如人类癌细胞系）进行基因组分析的新项目，这些项目的目标包括阐明癌症的致病机制以及癌症的基因组改变如何影响。其中一项努力是最近启动的癌症驱动发现计划 (CDDP)，该计划旨在识别 2% 或更多特定组织学癌症病例中获得“驱动突变”的基因。 CDDP 已启动，最初重点关注三种肿瘤类型——肺腺癌、结肠癌和卵巢癌——但也会考虑其他肿瘤类型。将具有统计能力来发现癌症中可能驱动致癌过程的新的经常性突变基因，该黄色任务支持的另一个计划是临床试验测序项目（CTSP），CCG 是其中的一员。与 DCTD 合作，对参加 NCI 赞助的临床试验的患者的癌症活检标本进行全面的基因组分析，目的是确定治疗反应和耐药性的分子基础 第三个 CCG 计划，称为人类癌症模型计划 (HCMP)。 ，将包括对体外或异种移植中新创建的人类癌症模型进行基因组分析。这项黄色任务不仅支持 CDDP、CTSP 和 HCMP 内的基因组分析，而且使 CCG 能够在其他队列中进行类似的分析。癌症解决癌症发病机制和治疗中关键问题的标本或模型。 该黄色任务支持进行上述基因组分析所需的一系列活动，首先，承包商将支持为 CCG 资助的项目获取组织样本和癌症模型。预计肿瘤的产生将主要来自于这些活动。 NCI 合作组或类似实体在大规模注释良好的临床试验中收集的样本，但不排除其他来源的组织，并且属于本任务订单的应计流程范围。样品和相关的临床数据将涉及以单一支付结构向参与机构报销少量金额。 其次，该黄色任务支持生物样本核心存储库 (BCR)，该存储库为 CCG 提供癌症活检样本的获取、分子分析物（DNA、RNA 和蛋白质）的衍生以及与 CCG 相关的临床数据的管理提供支持。此外，BCR 将制作文件（材料转让协议，MTA），对组织源站点 (TSS)、基因组表征中心之间的法律关系进行编纂。 （海湾合作委员会）和 BCR。 最后，该黄色任务支持建立基因组表征中心 (GCC)，该中心将从 BCR 提供的分析物中生成各种类型的分子数据，并以与 BCR 赞助的其他大规模基因组学项目兼容的格式存储所述数据。 CCG。数据存储将在项目办公室（PO）指定的数据库中完成。